Research and Markets (http://www.researchandmarkets.com/research/bb7e17/urinary_incontinen) has announced the addition of Global Markets Direct's new report "Urinary Incontinence - Pipeline Review, H1 2012" to their offering.

Global Markets Direct's, 'Urinary Incontinence - Pipeline Review, H1 2012', provides an overview of the Urinary Incontinence therapeutic pipeline. This report provides information on the therapeutic development for Urinary Incontinence, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Urinary Incontinence. 'Urinary Incontinence - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

• A snapshot of the global therapeutic scenario for Urinary Incontinence.
• A review of the Urinary Incontinence products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Coverage of products based on various stages of development ranging from discovery till registration stages.
• A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
• Coverage of the Urinary Incontinence pipeline on the basis of route of administration and molecule type.
• Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
• Key discontinued pipeline projects.

Reasons to buy

• Identify and understand important and diverse types of therapeutics under development for Urinary Incontinence.
• Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
• Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
• Devise corrective measures for pipeline projects by understanding Urinary Incontinence pipeline depth and focus of Urinary Incontinence therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

For more information visit http://www.researchandmarkets.com/research/bb7e17/urinary_incontinen.